# A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

> **NCT05660122** · — · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 2852 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Fexuprazan Hydrochloride

## Key facts

- **NCT ID:** NCT05660122
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-11
- **Primary completion:** 2024-12-26
- **Final completion:** 2025-08-11
- **Target enrollment:** 2852 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05660122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05660122, "A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05660122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*